Get started
Author

Maria Mazurkiewicz-Bełdzińska

Observed names: M. Mazurkiewicz-Bedziska, M. Mazurkiewicz-Bedzińska, M. Mazurkiewicz-Bełdzińska, Maria MAZURKIEWICZ-BEŁDZIŃSKA, Maria Mazurkiewicz Beldzinska, Maria Mazurkiewicz- Bełdzińska, Maria Mazurkiewicz-Beldinska, Maria Mazurkiewicz-Beldzinska, Maria Mazurkiewicz-Bełdzinska
Observed institution: Gdańsk Medical University
ORCID: 0000-0002-9405-5066
Observed ORCID: 0000-0002-9405-5066
OpenAlex ID: A5109534787
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
2018 · Elizabeth A Thiele, Eric D Marsh, et al. · The Lancet · 967
Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study
2022 · Claude Cances, Dmitry Vlodavets, et al. · Orphanet Journal of Rare Diseases · 44
PDF
FIREFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Infants with Type 1 Spinal Muscular Atrophy (SMA) (1302)
2020 · Laurent Servais, Giovanni Baranello, et al. · Neurology · 27
FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA)
2020 · Giovanni Baranello, Laurent Servais, et al. · European Respiratory Journal · 9
FIREFISH Part 2: 24-Month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA)
2021 · B. T. Darras, R. Masson, et al. · Neuropediatrics · 4
FIREFISH Part 2: 24-month Efficacy and Safety of Risdiplam in Infants with Type 1 Spinal Muscular Atrophy (SMA) (4126)
2021 · Basil T. Darras, Ricardo Masson, et al. · Neurology · 4
Pooled Safety Data from the Risdiplam Clinical Trial Development Program (4184)
2021 · Laurent Servais, Giovanni Baranello, et al. · Neurology · 4
Pooled Safety Data from the Risdiplam (RG7916) Clinical Trial Development Program (1267)
2020 · Giovanni Baranello, Enrico Bertini, et al. · Neurology · 4
Diagnostyka i leczenie padaczki u osób dorosłych — rekomendacje Polskiego Towarzystwa Neurologicznego
2016 · Konrad Rejdak, Rafał Rola, et al. · Polski Przegląd Neurologiczny · 3
Transition from paediatric to adult care in paediatric-onset neurological disorders in Europe: A survey and scoping review
2026 · Dana Craiu, Maria T. Papadopoulou, et al. · European Journal of Paediatric Neurology · 2
CMIP as a novel candidate gene for neurodevelopmental and neuropsychiatric disorders
2026 · Matthias De Wachter, Mathijs B. van der Lei, et al. · European Journal of Human Genetics · 1
PDF
423PRAINBOWFISH: 3-year efficacy and safety data of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
2025 · M. Mazurkiewicz-Bełdzińska, R. Finkel, et al. · Neuromuscular Disorders · 1
P230 Safety update: Risdiplam clinical trial program for spinal muscular atrophy (SMA)
2023 · G. Baranello, C. Chiriboga, et al. · Neuromuscular Disorders · 1
FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA) (P7-9.009)
2023 · Basil Darras, Giovanni Baranello, et al. · Neurology · 1
P.109 FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA)
2022 · L. Servais, G. Baranello, et al. · Neuromuscular Disorders · 1
FIREFISH Parts 1 and 2: 24-month Safety and Efficacy of Risdiplam in Type 1 SMA (S39.005)
2022 · Basil T. Darras, Odile Boespflug-Tanguy, et al. · Neurology · 1
FIREFISH Parts 1 and 2: 24-Month Safety and Efficacy of Risdiplam in Type 1 SMA
2021 · Ricardo Masson, Odile Boespflüg-Tanguy, et al. · 1
SMA – THERAPY
2020 · L. Servais, O. Bloespflug-Tanguy, et al. · Neuromuscular Disorders · 1
FP35-WE-04 Nonconvulsive status epilepticus in children and elderly patients – two different entities
2009 · M. Mazurkiewicz-Bedzińska, K. Niedzielska, et al. · Journal of the Neurological Sciences · 1
Abstract 6551: The Cardiac Natural History of ATP1A3 -Related Disorders
2026 · Sarah Macris, Mary Silzer, et al. · Circulation
Abstract 6191: Heart Rate-Lowering Anesthetics Exacerbate Risk of Ventricular Arrhythmias in Patients with ATP1A3-Associated Disease
2026 · Mary Silzer, Sarah Macris, et al. · Circulation
1.71eP Clinical characteristics and treatment outcomes in patients with spinal muscular atrophy and four SMN2 copies
2026 · Anna Lemska, Sylwia Studzińska, et al. · Neuromuscular Disorders
1.88P Real-world effectiveness of risdiplam in spinal muscular atrophy: a single-center experience compared with pivotal trials
2026 · Anna Lemska, Sylwia Studzinska, et al. · Neuromuscular Disorders
2.67eP Efficacy and safety of golodirsen and casimersen compared with placebo in Duchenne muscular dystrophy (ESSENCE): phase 3 results and post hoc analysis
2026 · Francesco Muntoni, Emma Ciafaloni, et al. · Neuromuscular Disorders
Age-Dependent Progression of Neurological Involvement in PRPP Deficiency: Insights from a Four-Generation Family and Systematic Review
2026 · Bartosz Rodziewicz, Mikołaj Kacperski, et al. · Biomolecules
Works count: 48
Citation count: 1,077
H-index: 4
I10-index: 3
Year
Topic
Type